OSCR
Oscar Health, Inc.
OSCR has the edge over SNY overall, supported by stronger fundamentals and stronger modeled upside.
SNY
Sanofi
SNY has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SNY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Healthy |
SNY's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over SNY in the historical PE scenario, which offers more potential upside but is not a forecast.
SNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $5.73 | -88% |
| Fair | 19x | $10.07 | -79% |
| Expensive | 31x | $16.50 | -66% |
| Current | 89x | $48.46 | — |
Historical ranges are pointers, not guarantees.
SNY's PE is 89x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SNY Forward outlook
There aren't enough analyst estimates for SNY to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
SNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.54 | -87% |
| Q1 2026 | $2.17 | -27% |
| Q4 2025 | $2.27 | -15% |
| Q3 2025 | $4.28 | +112% |
| Q2 2025 | $4.27 | +127% |
| Q1 2025 | $2.99 | +49% |
| Q4 2024 | $2.66 | +11% |
| Q3 2024 | $2.02 | -50% |
SNY's earnings per share have fallen from their peak: $0.54 over the past year, against $5.47 in late 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SNY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
SNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $13.7B | +15% |
| Q1 2026 | $12.5B | +6% |
| Q4 2025 | $13.6B | +60% |
| Q3 2025 | $14.6B | -7% |
| Q2 2025 | $11.9B | -5.7% |
| Q1 2025 | $11.8B | +9% |
| Q4 2024 | $8.5B | -37% |
| Q3 2024 | $15.7B | +11% |
SNY's revenue has picked up after three years of holding roughly level: $13.7B last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 19% | +5.6 points |
| Q1 2026 | 20% | -0.9 points |
| Q4 2025 | -8.5% | -16 points |
| Q3 2025 | 28% | +1.8 points |
| Q2 2025 | 14% | -0.3 points |
| Q1 2025 | 21% | +8.3 points |
| Q4 2024 | 7.5% | +4.7 points |
| Q3 2024 | 26% | +0.4 points |
SNY has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SNY on cash flow, with more consistent year-over-year improvement.
SNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $4.3B | +$4.3B |
| Q1 2026 | $1.9B | -20% |
| Q4 2025 | $1.8B | +$1.8B |
| Q3 2025 | $5.1B | +$5.1B |
| Q2 2025 | $0 | +$458.7M |
| Q1 2025 | $2.3B | +$2.3B |
| Q4 2024 | $0 | -100% |
| Q3 2024 | $0 | $0 |
SNY generated $13.1B in free cash flow over the past year, about six times what it generated the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -15.2M shares |
| 1 year | -3% | -74.6M shares |
| 3 years | -4.3% | -108M shares |
| 5 years | -4.4% | -111M shares |
| Available history | -4.4% | -111M shares |
SNY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $1.3B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $32.2M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SNY spent $1.3B buying back its own shares over the past year, after none the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over SNY on leverage, with a lower net debt burden relative to earnings.
SNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.0x | Healthy |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.0x | Very low |
| Q2 2024 | 2.1x | Moderate |
SNY's net debt is about 1.2 years of its operating earnings (EBITDA), up from less than a year a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.1 | Neutral |
| Stochastic | 86.8 | Overbought |
SNY's weekly RSI is 64 (neutral) and its Stochastic is 87 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over SNY on valuation relative to its sector.
SNY PE vs Healthcare Sector
| Metric | SNY | Sector median | Relative |
|---|---|---|---|
| PE | 89x | 26x | 244% above |
| PE % | 100 | 29 | 71 pts above |
SNY is trading at 89x earnings, a 244% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SNY on trend strength, trading above more of its moving averages.
SNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $42.9 | 13% above |
| 20 week MA | $43.4 | 12% above |
| 50 week MA | $45.1 | 7.5% above |
| 100 week MA | $47.9 | 1.1% above |
| 200 week MA | $49.4 | 1.9% below |
SNY has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 1.9% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SNY on returns for 2026, with the stronger performance.
SNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.9 | $47.5 | -6.7% |
| 2021 | $47.5 | $49.8 | +5% |
| 2022 | $49.8 | $48.5 | -2.6% |
| 2023 | $48.5 | $49.7 | +2.5% |
| 2024 | $49.7 | $48.7 | -2% |
| 2025 | $48.7 | $48.5 | -0.5% |
| 2026 YTD | $48.5 | $48.5 | 0% |
SNY has finished lower in four of the last six years. It's roughly flat so far in 2026.